Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,958 total articles

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Tonix Pharmaceuticals Holding Corp., a US-listed biotechnology company specializing in CNS and immunology treatments, announced its executive team's participation in BTIG Infectious Disease Day 2026, held virtually on June 16, 2026. The company focuses on commercial-stage products for fibromyalgia and migraines, while advancing a pipeline addressin…

Aqua Metals Selected as Industrial Partner on DOE-Funded Idaho National Laboratory Program Advancing Critical Minerals Refining

Aqua Metals Selected as Industrial Partner on DOE-Funded Idaho National Laboratory Program Advancing Critical Minerals Refining

Aqua Metals, Inc. has been selected as the industrial partner in a DOE-funded program led by Idaho National Laboratory to develop electrochemical methods for refining nickel and cobalt from lithium-ion battery recycling streams. This collaboration leverages Aqua Metals' pilot facilities and expertise to enhance domestic critical minerals refining t…

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Climb Bio announced initial Phase 1b clinical data demonstrating that Budoprutug, an anti-CD19 monoclonal antibody, exhibits an encouraging safety profile, robust B-cell depletion, and meaningful platelet response in heavily pretreated adult patients with primary immune thrombocytopenia (ITP). The data were presented at the European Hematology Asso…

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

Purple Biotech Ltd. presented new preclinical data at EACR 2026 showcasing its lead immunotherapy candidate IM1240, part of the CAPTN-3 platform. The data indicate significant improvements in pharmacokinetics, safety, and anti-tumor efficacy, particularly in immunotherapy-resistant cancers such as head and neck, bladder, and non-small cell lung can…

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

Nurix Therapeutics announced updated Phase 1a/b clinical trial results for bexobrutideg (NX-5948), an oral BTK degrader, demonstrating high objective response rates and durable progression-free survival in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients, including those with prior BTK inhibitor resista…

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Syndax Pharmaceuticals announced the publication and presentation of Phase 1/2 SAVE trial data evaluating an all-oral combination of Revuforj (revumenib), decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) characterized by NPM1 mutation, KMT2A rearrangement, or NUP98 rearrangement. The trial…

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease

AC Immune SA, a clinical-stage biopharmaceutical company listed on NASDAQ (ticker: ACIU), announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The grant will fund an extension of Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, an active immunotherapy targeting alpha-synuclein in early…

Pharvaris Announces Annual General Meeting of Shareholders

Pharvaris Announces Annual General Meeting of Shareholders

Pharvaris announced its Annual General Meeting of shareholders scheduled for June 26, 2026. The company is advancing its late-stage biopharmaceutical pipeline focused on oral bradykinin B2 receptor antagonists targeting hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Pharvaris is preparing marketing a…

Kimco Realty OP, LLC Announces Pricing of Upsized $525.0 Million Exchangeable Senior Notes Offering

Kimco Realty OP, LLC Announces Pricing of Upsized $525.0 Million Exchangeable Senior Notes Offering

Kimco Realty OP, LLC priced $525 million of 3.50% exchangeable senior notes due 2031, increased from $500 million, with proceeds to partially repurchase common stock and for general corporate purposes including debt repayment and acquisitions. Notes are exchangeable into Kimco common stock at a premium and carry optional redemption features. The of…

Agencia Comercial Spirits Ltd Announces Power Supply Agreements with PLN for Indonesia AI Data Center Project

Agencia Comercial Spirits Ltd Announces Power Supply Agreements with PLN for Indonesia AI Data Center Project

Agencia Comercial Spirits Ltd, a Taiwan-based whisky importer and distributor listed on NASDAQ, announced that its Indonesian subsidiary has entered into additional electricity supply agreements with Indonesian state-owned PLN to support its planned AI computing infrastructure project in Indonesia. The agreements establish a dual-feed power supply …

Compass Diversified Announces CEO Succession Plan

Compass Diversified Announces CEO Succession Plan

Compass Diversified (NYSE: CODI) announced that co-founder and CEO Elias Sabo will retire at the end of 2026. Zach Sawtelle, currently COO, will succeed him as CEO. The company reaffirmed its 2026 financial outlook, highlighted strong subsidiary performance, and is progressing with a review of the Management Services Agreement to better align incen…

Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics Announce Business Combination Agreement to Advance Precision Oncology

Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics Announce Business Combination Agreement to Advance Precision Oncology

Copley Acquisition Corp (NYSE: COPL), a SPAC, has entered into a definitive business combination agreement with Ignite Proteomics, a precision oncology company specializing in pathway-level protein analytics. The combined entity, Ignite Proteomics Holdings, Inc., plans to list on the New York Stock Exchange with a pro forma enterprise value of $150…

K-Tech Solutions Company Limited and Aurora AZ Energy Ltd. Announce Construction and Testing Progress on Initial 5 MW Capacity Phase of Joint Venture

K-Tech Solutions Company Limited and Aurora AZ Energy Ltd. Announce Construction and Testing Progress on Initial 5 MW Capacity Phase of Joint Venture

K-Tech Solutions Company Limited (Nasdaq: KMRK), in partnership with Aurora AZ Energy Ltd., has commenced construction and technical testing on the initial 5 MW capacity phase of their joint venture to develop large-scale computing infrastructure powered by wellhead natural gas in Alberta, Canada. This initial phase serves as proof-of-concept for a…

Cellectis Presents Final Phase 1 Results of Lasme-cel and  Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis reported final Phase 1 clinical trial results for lasme-cel, an allogeneic CAR-T therapy targeting CD22 in relapsed/refractory B-cell acute lymphoblastic leukemia, demonstrating a 100% overall response rate in the target Phase 2 population with manageable safety. Preliminary Phase 1 data of eti-cel, a dual CD20/CD22 CAR-T therapy for rela…

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion A/S unveiled new preclinical results for EVX-04, an AI-designed off-the-shelf therapeutic vaccine targeting endogenous retrovirus tumor antigens in acute myeloid leukemia (AML). The data demonstrates successful expression and secretion in human cells, robust immune activation across different immune profiles, and potential for targeted tumo…

PureCycle Announces Pricing of Concurrent Public Offerings of 4.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $395.0 Million

PureCycle Announces Pricing of Concurrent Public Offerings of 4.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $395.0 Million

PureCycle Technologies, Inc. announced the pricing of two concurrent public offerings: $250 million aggregate principal of convertible senior notes due 2032 at 4.75% interest and approximately 17.7 million shares of common stock, aiming to raise gross proceeds of $395 million. The net proceeds will primarily be used to repurchase existing higher-in…

FCHL to Hold Extraordinary General Meeting on June 29, 2026

FCHL to Hold Extraordinary General Meeting on June 29, 2026

Fitness Champs Holdings Limited, a leading aquatic sports education provider in Singapore listed on NASDAQ, announced an Extraordinary General Meeting (EGM) of shareholders to be held on June 29, 2026. The notice includes details on meeting logistics, voting eligibility, and access to relevant proxy materials. The company continues its focus on swi…

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc., a biotechnology company specializing in bioengineered human tissues, announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, aiming to raise $50 million before expenses. The company plans to use the proceeds to fund commercialization of its FDA-approved product Symvess, suppo…

Five Star Bancorp Names Cliff Cooper as Executive Vice President / Food, Agribusiness & Diversified Industries President

Five Star Bancorp Names Cliff Cooper as Executive Vice President / Food, Agribusiness & Diversified Industries President

Five Star Bancorp has promoted Cliff Cooper to Executive Vice President and President of the Food, Agribusiness & Diversified Industries vertical. Cooper brings over 35 years of banking experience in the agribusiness sector and has been with Five Star Bank since 2025. His leadership is expected to enhance the bank's strategic initiatives and deepen…